Bexion Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Based In Covingtonkentuckythe Company Focuses On Developing Innovative Therapies For Oncology And Central Nervous System Disorderswith A Team Of Approximately 31 Employeesbexion Reported $2 Million In Annual Revenue As Of 2024Bexion Is Advancing Its Lead Productbxq 350A First In Class Sphingolipid Metabolism Modulator Aimed At Treating Solid Tumors And Chemotherapy Induced Peripheral Neuropathycipn Currentlybxq 350 Is In Phase 1B 2 Clinical Trialswith Recent Enrollment Completion For A Study In Metastatic Colorectal Cancerthe Company Is Also Exploring The Potential Of Bxq 350 In Additional Cancer Types And Neuropathic Pain Applicationsled By Ceo Jim Beach And Founder Ray Takigikubexion Emphasizes A Patient Centric Approach To Address Unmet Medical Needs In Cancer Treatment And Related Complicationsthe Company Is Committed To Improving Patient Outcomes Through Its Innovative Biologic Therapies
United States
